PRX Plus (5x4ml)

What it is

PRX Plus is WiQo's next-generation biorevitalizing peel treatment that stimulates fibroblasts and collagen synthesis in the deep skin layers, without superficial peeling or social downtime.

Mechanism of action

Ammonium Trichloroacetate (ATCA) 33% combined with Homocysteic acid (HoA) 2% — a molecule not found in any other cosmetic or medical device product on the market — stimulates NMDA receptors in the epidermis and upper dermis for a gentler, more superficial effect than PRX-T33. Citric acid/phytic acid rounds out the formula, supporting a smoother, more even skin tone with minimal downtime.

Indications and treatment areas

Skin revitalization, uneven tone, visible pores, excess sebum production and early signs of aging. Face, neck, décolletage, hands and body.

Treatment protocol

• Application: topical, massaged into the skin — no needles or injections.
• Frequency: 4 treatments every 2 weeks, follow-up after 45 days, repeat course after 6 months.

Expected results

Clinically documented after 2 weeks: −40.4% wrinkle depth, −46.5% visible pores, −30.2% texture, −18.6% sebum production, −10.7% UV spots, −17% under-eye wrinkles, with minimal downtime.

Documentation and traceability

CE-marked medical device (Class I). Manufactured by WiQo Med, Italy.

Composition: Ammonium Trichloroacetate (ATCA) 33%, Homocysteic acid (HoA) 2%, Citric acid/Phytic acid — 5 × 4 ml vials per package.

Profesjonell PRX-behandling basert på homocysteinsyre og ammoniumtrikloracetat – et annet syresystem enn PRX-T33. Påføres topikalt uten nåler og gir ingen synlig eksfoliering. Produsenten posisjonerer PRX Plus for moden og fotoskadet hud: lysere og jevnere hudtone, redusert pigmentering, synlig laksitet, poreutseende og hudtetthet. Behandlingen tar ca. 15 minutter. Antall behandlinger og intervall fastsettes av behandlende lege. Se produsentens protokoll for detaljert påføringsprosedyre.